Lorazepam is typically detectable in urine for about 1 to 6 days after a single dose. For people who have been taking it regularly over weeks or months, that window can stretch significantly longer. The exact timeline depends on how much you’ve taken, how long you’ve been taking it, and how efficiently your body processes the drug.
Typical Detection Windows
After a single therapeutic dose, lorazepam and its breakdown products usually show up on a urine test for 1 to 3 days. This is shorter than many other drugs in the same class because lorazepam has a relatively short half-life of about 14 hours, meaning your body eliminates half the drug roughly every 14 hours.
With regular or heavy use, the detection window extends well beyond that 3-day mark. Benzodiazepines as a class can be detected in urine for up to 6 weeks after prolonged, heavy use of longer-acting versions. Lorazepam falls on the shorter end of that spectrum, but chronic daily use can still push detection out to 1 to 3 weeks as the drug accumulates in your system over time.
How Your Body Processes Lorazepam
Lorazepam is broken down in the liver through a process called glucuronidation, which converts it into an inactive compound (lorazepam glucuronide) that your kidneys then flush out in urine. This is actually a simpler metabolic pathway than most benzodiazepines use. The drug also recirculates between your liver and intestines before being fully eliminated, which can slightly extend how long traces remain in your body.
It’s the inactive metabolite, not the original drug, that urine tests primarily pick up. Since this metabolite is cleared through the kidneys, anything that slows kidney function also slows elimination.
What Affects How Quickly You Clear It
Several factors can shorten or lengthen your personal detection window:
- Age: Older adults clear lorazepam more slowly and are more sensitive to its effects. Reduced kidney and liver efficiency with age means the drug and its metabolites linger longer.
- Kidney function: Since the metabolite is eliminated through the kidneys, impaired kidney function has a major impact. In people with kidney disease, the half-life of lorazepam’s metabolite increases by about 55%. For people on dialysis, it increases by about 125%, more than doubling the time it takes to clear.
- Liver function: Interestingly, lorazepam is one of the safer benzodiazepines for people with liver problems. It bypasses the liver’s main drug-processing system and uses a more direct pathway, so liver disease has relatively little effect on how quickly it’s metabolized.
- Dosage and duration of use: Higher doses and longer periods of use mean more drug stored in your body’s tissues, which takes longer to fully wash out.
- Body composition and metabolism: Individual differences in metabolic rate, body fat percentage, and overall health all play a role, though these are harder to quantify than the factors above.
How Urine Drug Tests Detect It
Standard urine drug screens don’t test specifically for lorazepam. They test for benzodiazepines as a group using an immunoassay, which is a quick, relatively inexpensive screening method. The typical cutoff for a positive result is 100 ng/mL, meaning anything below that concentration is reported as negative even if trace amounts are present.
If the initial screen comes back positive, a second confirmatory test can identify the specific benzodiazepine involved. This confirmation step uses more precise laboratory techniques and can distinguish lorazepam from other drugs in the same class.
One important wrinkle: lorazepam can sometimes be missed by standard immunoassay screens altogether. These tests are designed to detect the most common benzodiazepine metabolites, and lorazepam’s metabolic pathway is different enough that it occasionally produces a false negative, particularly at lower doses or toward the tail end of the detection window.
False Positives From Other Medications
If you haven’t taken lorazepam or any benzodiazepine but test positive, certain medications are known to cause false positives on the initial screening. The antidepressant sertraline (Zoloft) and the anti-inflammatory drug oxaprozin (Daypro) have both been documented as triggers. Sertraline and its breakdown products can cross-react with the immunoassay at high concentrations, producing a result that looks like a benzodiazepine positive.
A confirmatory test will sort this out, since it can tell the difference between actual benzodiazepine metabolites and these look-alikes. If you’re taking either of these medications and face a drug screen, mentioning them beforehand can save confusion.